MetrioPharm Receives Orphan Drug Designation for the Treatment of Duchenne Muscular Dystrophy
FDA grants orphan drug designation for MetrioPharm’s lead compound MP1032 for the treatment of Duchenne muscular dystrophy (DMD)DMD is a designated orphan disease in both Europe and the U.S.MetrioPharm’s development objectives: better…